Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

Researchers around the world are collaborating to provide solutions to immediate and future challenges.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.

Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.

A strong background in biological research prepared Daniel Rooks for his role in shaping the early clinical development of new medicines